CMV drug review

Marketing Vistide

Gilead Sciences Inc. estimated its Vistide held a 22 percent share of the CMV market versus the two other iv products - ganciclovir and foscarnet - at the end of September. Based on a sample of 103 AIDS physicians, the company found 90 percent awareness of its drug among a range of physicians including general practitioners, infectious disease specialists and some ophthalmologists. Of these, 40 percent had used Vistide in at least one patient.

The company has two key marketing issues to address: nephrotoxicity and making its clinical trial data more widely known.